bpc 157 for cancer patients BPC-157 BPC-157 Peptide Therapy | New

BPC-157 is not FDA-approved for any indication

When activated, the mast cells in the skin release mediators (histamines, tryptase, TNF-alpha, CXCL9, etc.) that cause inflammation, flushing, itching, or burning.[ref] Related article: Rosacea, underlying causes, genetic susceptibility Dermatographism and mast cell activation syndrome: In a survey of mast cell activation syndrome, dermatographism was found in 89% of the patients.[ref] Dermatographism is when you get welts or raised red lines when you scratch your skin lightly

Some researchers think that vitamin C injections can make chemotherapy work better or prevent some chemotherapy side effects

Already in effect (January 1, 2026): Standard PA decisions within 7 calendar days (down from 14) Urgent PA decisions within 72 hours Specific denial reasons required on every denial (not just not medically necessary) Applies to Medicare Advantage, Medicaid managed care, CHIP, and ACA Marketplace plans Coming March 31, 2026: Payers must publicly report PA metrics for calendar year 2025: approval/denial rates, average decision times, and appeals outcomes Providers will be able to compare payer performance for the first time Coming January 1, 2027: FHIR-based Prior Authorization APIs required providers check PA requirements, submit requests, and receive decisions electronically through their EHR Expected to reduce average PA processing time from days to minutes for standard requests Medicare WISeR Model (live in AZ and WA): The Wasteful and Inappropriate Services Reduction pilot launched January 2026 in six states including Arizona and Washington